Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 27312053

Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Oncol
Publication date
2016 Aug
First author
Goto K

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2016 Aug;17(8):1033-1035. doi: 10.1016/S1470-2045(16)30160-7.
    note
    Source null
    related pmid
    27312052
    relationship
    Comment in
  2. citation
    J Thorac Dis. 2016 Sep;8(9):2360-2364. doi: 10.21037/jtd.2016.09.28.
    note
    Source null
    related pmid
    27746976
    relationship
    Comment in
  3. citation
    Ann Transl Med. 2016 Oct;4(Suppl 1):S65. doi: 10.21037/atm.2016.10.68.
    note
    Source null
    related pmid
    27868033
    relationship
    Comment in
  4. citation
    Transl Cancer Res. 2016 Nov;5(Suppl 6):S1142-S1144. doi: 10.21037/tcr.2016.11.22.
    note
    Source null
    related pmid
    28523239
    relationship
    Comment in

Authors and identifiers

  1. name
    Goto K
    type
    Author
  2. name
    Ohe Y
    type
    Author
  3. name
    Shibata T
    type
    Author
  4. name
    Seto T
    type
    Author
  5. name
    Takahashi T
    type
    Author
  6. name
    Nakagawa K
    type
    Author
  7. name
    Tanaka H
    type
    Author
  8. name
    Takeda K
    type
    Author
  9. name
    Nishio M
    type
    Author
  10. name
    Mori K
    type
    Author
  11. name
    Satouchi M
    type
    Author
  12. name
    Hida T
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Goto K
    type
    Author
  2. name
    Ohe Y
    type
    Author
  3. name
    Shibata T
    type
    Author
  4. name
    Seto T
    type
    Author
  5. name
    Takahashi T
    type
    Author
  6. name
    Nakagawa K
    type
    Author
  7. name
    Tanaka H
    type
    Author
  8. name
    Takeda K
    type
    Author
  9. name
    Nishio M
    type
    Author
  10. name
    Mori K
    type
    Author
  11. name
    Satouchi M
    type
    Author
  12. name
    Hida T
    type
    Author
bibliography ids
  1. nci-bib-87926399a418f35cc131fc41
book metadata
content sha256
a4f4e8dac03abd62c333bb053e14fa1c4fbcd6671272ed1a6b4387c952c53e4b
document type
citation
dois
  1. 10.1016/S1470-2045(16)30104-8
electronic publication date
display
2016 Jun 14
precision
day
year
2016
evidence scope
bibliographic_metadata_only
id
pubmed:27312053
immutable id
pubmed:27312053@a4f4e8dac03abd62c333bb053e14fa1c4fbcd6671272ed1a6b4387c952c53e4b
journal
abbreviation
Lancet Oncol
issn electronic
1474-5488
issn print
1470-2045
issue
8
name
The Lancet. Oncology
nlm unique id
100957246
pages
1147-1157
volume
17
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2016 Aug;17(8):1033-1035. doi: 10.1016/S1470-2045(16)30160-7.
    note
    Source null
    related pmid
    27312052
    relationship
    Comment in
  2. citation
    J Thorac Dis. 2016 Sep;8(9):2360-2364. doi: 10.21037/jtd.2016.09.28.
    note
    Source null
    related pmid
    27746976
    relationship
    Comment in
  3. citation
    Ann Transl Med. 2016 Oct;4(Suppl 1):S65. doi: 10.21037/atm.2016.10.68.
    note
    Source null
    related pmid
    27868033
    relationship
    Comment in
  4. citation
    Transl Cancer Res. 2016 Nov;5(Suppl 6):S1142-S1144. doi: 10.21037/tcr.2016.11.22.
    note
    Source null
    related pmid
    28523239
    relationship
    Comment in
outcomes validated
false
pmid
27312053
provenance
batch id
fe5a46c92522c34737e8
provider
NCBI PubMed ESummary
record sha256
b56f8d6c613f33eecbe567c154622ae207e226e4b0242453be37d9a72e2758fd
response sha256
2c7bacd02d2ece3813daf1a0f92260c22884bd9268942fcca2088ab229bfb4d1
retrieved at
2026-09-09T23:47:17.939307+00:00
publication date
display
2016 Aug
precision
month
year
2016
publication types
  1. Clinical Trial, Phase III
  2. Comparative Study
  3. Journal Article
  4. Multicenter Study
  5. Randomized Controlled Trial
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/27312053/
title
Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial.

Preserved source evidence · Not medical advice